Last Update 03 Jun 26

PRGO: Future Upside Will Rely On Infant Nutrition Execution

Analysts have modestly raised their price target on Perrigo to $16.50, citing updated assumptions for the discount rate and future P/E while keeping fair value and long term growth expectations essentially unchanged.

Analyst Commentary

Recent commentary around valuation work for Perrigo focuses on how updated discount rate and P/E assumptions affect the risk and return profile rather than changing the core business outlook.

Bullish Takeaways

Bullish analysts view the updated discount rate and P/E framework as a cleaner way to reflect current market conditions without needing to change longer term growth assumptions.
The modestly higher price target suggests confidence that Perrigo can execute closely in line with existing forecasts, which supports the current fair value range used in their models.
Keeping long term growth expectations steady while adjusting price target inputs points to an assessment that near term valuation math has shifted more than the underlying business thesis.
The incremental target lift is framed as a refinement, which bullish analysts present as a sign that their prior work on Perrigo’s execution and cash flow outlook remains intact.

Bearish Takeaways

Bearish analysts may see the reliance on updated discount rate and future P/E assumptions, with limited change to fundamental forecasts, as a reminder that much of the upside case still leans on valuation mechanics rather than new information on operations.
The fact that fair value and long term growth assumptions stay effectively unchanged can be read as a signal that there is no fresh evidence yet to support a stronger re rating based on execution alone.
Some cautious views focus on the sensitivity of Perrigo’s target to inputs like the discount rate, which can move with market conditions and may not reflect company specific progress.
The modest size of the target adjustment may suggest to more cautious readers that, while the stock screens reasonably on the updated metrics, the margin of safety in the current valuation still needs close monitoring.

What's in the News

Perrigo reported goodwill impairment charges of US$330.8 million for the quarter ended March 28, 2026, compared with US$1.2 million a year earlier, according to Key Developments.
The company reaffirmed earnings guidance for fiscal 2026, with expected total net sales growth in a range from a 5.5% decline to a 1.5% decline, according to Key Developments.
The U.S. International Trade Commission initiated an investigation involving certain over the counter topical lidocaine patches that includes Perrigo among multiple respondents, following a complaint from J.A.R Laboratories LLC, according to Key Developments.
A rumor involving Perrigo was highlighted in the Betaville blog, according to periodical coverage.

Valuation Changes

Fair Value: Held steady at $16.50, indicating no change in the central valuation estimate.
Discount Rate: Risen slightly from 9.29% to 9.77%, implying a modestly higher required return in the model.
Revenue Growth: Kept effectively unchanged at about 3.0%, with only a minimal adjustment in the underlying assumption.
Net Profit Margin: Maintained at roughly 1.75x in the model, with only a very small technical revision to the input.
Future P/E: Increased slightly from 40.79x to 41.63x, reflecting a marginally higher multiple applied to projected earnings.

23 views

Key Takeaways

Strong consumer shift toward store-brand OTC and structural industry tailwinds are driving sustainable revenue growth and stable demand for Perrigo's core product segments.
Portfolio simplification and operational efficiency initiatives are enhancing profitability, supporting innovation investment, and accelerating the company's financial deleveraging.
Weak demand, fierce competition, low pricing power, and operational challenges threaten Perrigo's ability to grow revenue, protect margins, and sustain long-term market share.

Catalysts

About Perrigo

Provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.What are the underlying business or industry changes driving this perspective?

Increasing consumer cost-consciousness is driving stronger adoption of store-brand (private label) OTC products, with Perrigo reporting accelerated unit and volume share gains; this structural shift is expanding Perrigo's addressable market and supports enduring top-line revenue growth.
The aging global population and rising consumer interest in self-care and wellness continue to create longer-term demand tailwinds for Perrigo's OTC and nutrition products, providing stable, defensive revenue streams even in periods of macro uncertainty.
Recent new business wins in US store-brand OTC have outpaced distribution losses for the first time since the 2024 reset, with net new contract gains expected to add $75M+ to sales in the second half-directly supporting a step-change in revenue growth and operating income.
Strategic portfolio simplification, including the recent sale of the Dermacosmetics business, allows Perrigo to focus investment on core, higher-growth segments, bolstering gross and operating margins and accelerating deleveraging.
Ongoing operational initiatives like Project Energize and supply chain reinvention are generating $150M–$200M in savings, funding innovation and margin-accretive investments, which are expected to further improve gross margins and net earnings over time.

Perrigo Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Perrigo's revenue will remain fairly flat over the next 3 years.
Analysts assume that profit margins will increase from -42.9% today to 1.8% in 3 years time.
Analysts expect earnings to reach $73.4 million (and earnings per share of $0.52) by about June 2029, up from -$1.8 billion today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 41.9x on those 2029 earnings, up from -0.8x today. This future PE is greater than the current PE for the US Pharmaceuticals industry at 14.8x.
Analysts expect the number of shares outstanding to grow by 0.57% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 9.77%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Ongoing soft category consumption in key markets, including declining total category consumption in the U.S. and decelerating consumption in the EU, could indicate underlying secular weakness in demand for OTC and self-care products, which would limit Perrigo's ability to drive sustained top line (revenue) growth over the long term.
Increasing competitive intensity in the infant formula and OTC markets-with heavy promotion, new product launches from competitors, and non-optimal shelf placement-suggests that Perrigo may struggle to maintain or grow market share, potentially constraining both revenue and net margins.
The company's dependence on volume-driven, private label and store brand products-with historically limited pricing power-makes it vulnerable to cost inflation (e.g., raw materials, tariffs) that could compress gross and net margins if cost offsets and price increases are not fully realized.
Product quality and supply chain challenges, such as the recent isolated infant formula production scrap event, introduce risk of variable production costs, lost sales, and potential reputational damage, all of which could negatively impact margins and future earnings if recurring or if quality issues arise.
Slower-than-expected recovery and ramp-up in key businesses (notably infant formula) and headwinds from possible continued importation of foreign products (e.g., European organic formula) highlight structural industry risks and regulatory uncertainties, possibly constraining both Perrigo's market share and long-term revenue/earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $16.5 for Perrigo based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $20.0, and the most bearish reporting a price target of just $14.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $4.2 billion, earnings will come to $73.4 million, and it would be trading on a PE ratio of 41.9x, assuming you use a discount rate of 9.8%.
Given the current share price of $10.46, the analyst price target of $16.5 is 36.6% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Perrigo?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

PRGO: Profit Margins And Operational Strength Will Support Long-Term Upside Potential